- SEK27.86bn
- SEK25.86bn
- SEK2.00bn
Brief: Bioarctic's Leqembi Approved In UK For Treatment Of Early Alzheimer's
Brief: UK's MHRA Approves Eisai-Biogen's Alzheimer's drug
Brief: UK's NICE Says Benefits Of Alzheimer’S Treatment Lecanemab Too Small To Justify Cost To NHS
Brief: Bioarctic Updates Regarding Rumors Of Imminent Approval Of Lecanemab In Great Britain
Brief: Leqembi Approved For The Treatment Of Alzheimer's Disease In The UAE
Brief: BioArctic Says Leqembi Approved For The Treatment Of Alzheimer's Disease In UAE
Brief: Bioarctic says Long-Term Lecanemab Data Show Increased Patient Benefit With Maintained Safety Profile
Brief: Committee For Medicinal Products Has Adopted Negative Opinion On BioArctic's Lecanemab For EU
Brief: BioArctic's Leqembi Approved For Treatment Of Alzheimer's In Israel
Brief: Bioarctic Says Co & Eisai Announced Today That Leqembi Has Been Approved For Treatment Of Alzheimer's Disease In Israel
Brief: Bioarctic AB Says Leqembi Approved For Treatment Of Alzheimer's Disease In Hong Kong
Eisai and Biogen launch Alzheimer's drug Leqembi in China
Brief: BioArctic says Launched In China
Brief: Bioarctic Says FDA Accepts Filing Of Leqembi Sbla For IV Maintenance Dosing
Brief: BioArctic's Leqembi Approved In South Korea
Brief: Bioarctic AB Says No Dividend Is Paid For Financial Year 2023
Brief: BioArctic Q1 Operating Profit SEK -73.1 Million
Brief: BioArctic Says Eisai Projects Leqembi Revenue To Total JPY 56.5 Billion For FY 2024
Brief: BioArctic Gets Royalty Of SEK 18 Mln For Leqembi Q1 Sales